~~<i id='C7A7755926'><strike id='C7A7755926'><tt id='C7A7755926'><pre id='C7A7755926'></pre></tt></strike></i>~~

Home» explore» hotspot

hotspot

author：entertainment 2025-10-01 05:28:05 Page View：3945

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How a scoliosis diagnosis changed the life of one young dancer
Next article： Peter Hotez and the public health issue of online harassment

comprehensive

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

3 trends to watch in health tech's hiring outlook for 2024

ChristineKao/STATHealthtechhopefulsmightoncehavebeenusedtoawealthofjoboptions,especiallyinthepandemi

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

J&J to buy cancer drug developer Ambrx Biopharma

AP/RichardDrewJohnson&JohnsonsaidMondaythatitwouldpurchaseAmbrxBiopharmafornearly$2billion,picki